Zhao Na, Liu Hongjun, Zhang Aifen, Wang Min
Department of Otolaryngology, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China.
Department of Return Visit Office, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China.
Oncol Lett. 2020 Nov;20(5):213. doi: 10.3892/ol.2020.12076. Epub 2020 Sep 8.
The present study aimed to investigate the expression levels and clinical significance of microRNA (miR)-203 and miR-133b in laryngeal carcinoma. A total of 154 patients with laryngeal carcinoma (research group) along with 100 healthy individuals (control group) were enrolled in the study. The patients were admitted to Yidu Central Hospital of Weifang (Weifang, China) from February 2016 to October 2018. Fasting venous blood (5 ml) was extracted from all subjects to determine the expression levels of serum miR-203 and miR-133b by reverse transcription-quantitative polymerase chain reaction (PCR) and to compare them among patients with different pathological characteristics. Receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic values of miR-203 and miR-133b for laryngeal carcinoma. The research group showed significantly lower expression levels of miR-203 and miR-133b than the control group (P<0.05). According to ROC curve analysis, when the cut-off value was 0.659, the sensitivity and specificity of miR-203 in diagnosing laryngeal carcinoma were 60.00 and 90.26%, respectively, whereas when the cut-off value was 1.398, the sensitivity and specificity of miR-133b were 55.00 and 87.66%, respectively. The sensitivity and specificity of the joint detection were 70.00 and 83.77%, respectively, when the cut-off value was 0.416. In the research group, miR-203 was expressed significantly different in patients with different pathological stages and tumor types (P<0.050). The expression of miR-133b varied significantly in patients with different pathological stages, differentiation degrees and lymph node metastasis (P<0.050). In conclusion, miR-203 and miR-133b were expressed at low levels in patients with laryngeal carcinoma. The expression of miR-203 was related to tumor-node-metastasis (TNM) stage and tumor type, whereas the expression of miR-133b was related to TNM stage, differentiation degree, as well as lymph node metastasis. Joint detection of miR-203 and miR-133b is expected to be an excellent marker for the diagnosis and treatment of laryngeal carcinoma.
本研究旨在探讨微小RNA（miR）-203和miR-133b在喉癌中的表达水平及临床意义。本研究共纳入154例喉癌患者（研究组）和100例健康个体（对照组）。患者于2016年2月至2018年10月入住潍坊市益都中心医院（中国潍坊）。采集所有受试者5ml空腹静脉血，采用逆转录-定量聚合酶链反应（PCR）测定血清miR-203和miR-133b的表达水平，并比较不同病理特征患者之间的表达水平。绘制受试者工作特征（ROC）曲线，分析miR-203和miR-133b对喉癌的诊断价值。研究组miR-203和miR-133b的表达水平显著低于对照组（P<0.05）。根据ROC曲线分析，当截断值为0.659时，miR-203诊断喉癌的灵敏度和特异度分别为60.00%和90.26%，而当截断值为1.398时，miR-133b的灵敏度和特异度分别为55.00%和87.66%。当截断值为0.416时，联合检测的灵敏度和特异度分别为70.00%和83.77%。在研究组中，miR-203在不同病理分期和肿瘤类型的患者中表达差异有统计学意义（P<0.050）。miR-133b在不同病理分期、分化程度和淋巴结转移的患者中表达差异有统计学意义（P<0.050）。综上所述，miR-203和miR-133b在喉癌患者中表达水平较低。miR-203的表达与肿瘤-淋巴结-转移（TNM）分期和肿瘤类型有关，而miR-133b的表达与TNM分期、分化程度以及淋巴结转移有关。miR-203和miR-133b的联合检测有望成为喉癌诊断和治疗的优良标志物。
